Mycobacterium Infections
13
6
6
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.7%
1 terminated out of 13 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Study of Mycobacterial Infections
Training Protocol on the Natural History of Tuberculosis
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
Gene Expression Profiles in Spinal Tuberculosis.
M. Avium WGS During Mav-PD Treatment
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)
Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
A Single Ascending Dose Study of BTZ043
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens
Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections